A successful case of dupilumab treatment for severe uremic pruritus

Jonathan I. Silverberg; Joaquin Brieva

doi:10.1016/j.jdcr.2019.01.024

A successful case of dupilumab treatment for severe uremic pruritus

Jonathan I. Silverberg^*, Joaquin Brieva

^*Corresponding author for this work

Dermatology

Research output: Contribution to journal › Article › peer-review

24 Scopus citations

Original language	English (US)
Pages (from-to)	339-341
Number of pages	3
Journal	JAAD Case Reports
Volume	5
Issue number	4
DOIs	https://doi.org/10.1016/j.jdcr.2019.01.024
State	Published - Apr 2019

Funding

Conflicts of interest: Dr Silverberg served as a consultant and/or advisory board member for Abbvie, Asana, Dermavant, Dermira, Eli Lilly, Galderma, GlaxoSmithKline, Glenmark, Kiniksa, Leo, Menlo, Pfizer, Regeneron-Sanofi. He also received honoraria from Realm, was a speaker for Regeneron-Sanofi, and received research grants from GlaxoSmithKline. Dr Silverberg is supported by the Dermatology Foundation. Dr Brieva has no conflicts to disclose. Funding sources: None. Conflicts of interest: Dr Silverberg served as a consultant and/or advisory board member for Abbvie, Asana, Dermavant, Dermira, Eli Lilly, Galderma, GlaxoSmithKline, Glenmark, Kiniksa, Leo, Menlo, Pfizer, Regeneron-Sanofi. He also received honoraria from Realm, was a speaker for Regeneron-Sanofi, and received research grants from GlaxoSmithKline. Dr Silverberg is supported by the Dermatology Foundation. Dr Brieva has no conflicts to disclose.

Keywords

itch
scratch
treatment
uremic pruritus

ASJC Scopus subject areas

Dermatology

Access to Document

10.1016/j.jdcr.2019.01.024

Cite this

@article{3f0314455e53422fa550b6994e3ad6a0,

title = "A successful case of dupilumab treatment for severe uremic pruritus",

keywords = "itch, scratch, treatment, uremic pruritus",

author = "Silverberg, \{Jonathan I.\} and Joaquin Brieva",

note = "Funding Information: Conflicts of interest: Dr Silverberg served as a consultant and/or advisory board member for Abbvie, Asana, Dermavant, Dermira, Eli Lilly, Galderma, GlaxoSmithKline, Glenmark, Kiniksa, Leo, Menlo, Pfizer, Regeneron-Sanofi. He also received honoraria from Realm, was a speaker for Regeneron-Sanofi, and received research grants from GlaxoSmithKline. Dr Silverberg is supported by the Dermatology Foundation. Dr Brieva has no conflicts to disclose. Funding sources: None. Conflicts of interest: Dr Silverberg served as a consultant and/or advisory board member for Abbvie, Asana, Dermavant, Dermira, Eli Lilly, Galderma, GlaxoSmithKline, Glenmark, Kiniksa, Leo, Menlo, Pfizer, Regeneron-Sanofi. He also received honoraria from Realm, was a speaker for Regeneron-Sanofi, and received research grants from GlaxoSmithKline. Dr Silverberg is supported by the Dermatology Foundation. Dr Brieva has no conflicts to disclose.",

year = "2019",

month = apr,

doi = "10.1016/j.jdcr.2019.01.024",

language = "English (US)",

volume = "5",

pages = "339--341",

journal = "JAAD Case Reports",

issn = "2352-5126",

publisher = "Elsevier Inc.",

number = "4",

}

TY - JOUR

T1 - A successful case of dupilumab treatment for severe uremic pruritus

AU - Silverberg, Jonathan I.

AU - Brieva, Joaquin

N1 - Funding Information: Conflicts of interest: Dr Silverberg served as a consultant and/or advisory board member for Abbvie, Asana, Dermavant, Dermira, Eli Lilly, Galderma, GlaxoSmithKline, Glenmark, Kiniksa, Leo, Menlo, Pfizer, Regeneron-Sanofi. He also received honoraria from Realm, was a speaker for Regeneron-Sanofi, and received research grants from GlaxoSmithKline. Dr Silverberg is supported by the Dermatology Foundation. Dr Brieva has no conflicts to disclose. Funding sources: None. Conflicts of interest: Dr Silverberg served as a consultant and/or advisory board member for Abbvie, Asana, Dermavant, Dermira, Eli Lilly, Galderma, GlaxoSmithKline, Glenmark, Kiniksa, Leo, Menlo, Pfizer, Regeneron-Sanofi. He also received honoraria from Realm, was a speaker for Regeneron-Sanofi, and received research grants from GlaxoSmithKline. Dr Silverberg is supported by the Dermatology Foundation. Dr Brieva has no conflicts to disclose.

PY - 2019/4

Y1 - 2019/4

KW - itch

KW - scratch

KW - treatment

KW - uremic pruritus

UR - http://www.scopus.com/inward/record.url?scp=85063743182&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063743182&partnerID=8YFLogxK

U2 - 10.1016/j.jdcr.2019.01.024

DO - 10.1016/j.jdcr.2019.01.024

M3 - Article

C2 - 30993160

AN - SCOPUS:85063743182

SN - 2352-5126

VL - 5

SP - 339

EP - 341

JO - JAAD Case Reports

JF - JAAD Case Reports

IS - 4

ER -

A successful case of dupilumab treatment for severe uremic pruritus

Funding

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this